Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ct-1578. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 20/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 20/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 3/20 | 1.00 |
| ▸ | TYK2 | P29597 | 18/20 | 1.00 |
| ▸ | JAK1 | P23458 | 16/20 | 1.00 |
| ▸ | JAK3 | P52333 | 15/20 | 1.00 |
| ▸ | CDK2 | P24941 | 13/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.71 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | STK16 | O75716 | 1/20 | 0.71 |
| ▸ | STK10 | O94804 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | PRKCB | P05771 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ct-1578 SCHEMBL29456953 | 1.00 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 | |
| Ct-1578 SCHEMBL17594734 | 1.00 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 | |
| Ct-1578 SCHEMBL29379113 | 1.00 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 | |
| SCHEMBL823948 | 0.92 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 | |
| Ct-1578 SCHEMBL11895184 | 0.91 | JAK2 (0.82) | JAK2FLT3TYK2JAK1JAK3 | |
| SCHEMBL1108266 | 0.86 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 | |
| SCHEMBL1108260 | 0.86 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 | |
| SCHEMBL1108258 | 0.84 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 | |
| SCHEMBL1108226 | 0.84 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 | |
| Pacritinib SCHEMBL31537559 | 0.83 | JAK2 (1.00) | JAK2FLT3TYK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062074-B2 | (9E)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt | CTI BIOPHARMA CORP. (US) | 2015-06-23 | — | — | US | claimed |
| EP-2454266-B1 | 9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZA- TETRACYCLO[18.3.1.1(2,5).1(14)18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | CELL THERAPEUTICS INC (US) | 2013-07-10 | — | — | EP | claimed |
| US-20120196876-A1 | (9E)-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZA-TETRACYCLO[18.3.1.1(2.5).1(14,18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| WO-2011008172-A1 | 9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZA- TETRACYCLO[18.3.1.1(2,5).1(14)18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | S*BIO PTE LTD (SG) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008172-A1 | 9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZA- TETRACYCLO[18.3.1.1(2,5).1(14)18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | S*BIO PTE LTD (SG) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008172-A1 | 9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZA- TETRACYCLO[18.3.1.1(2,5).1(14)18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | S*BIO PTE LTD (SG) | 2011-01-20 | — | — | WO | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | JAK2 1/4885FLT3 22/4885CSF1R 529/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | JAK2 1/4885FLT3 78/4885CSF1R 833/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | JAK2 468/4885FLT3 645/4885CSF1R 4155/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | JAK2 1/4885FLT3 171/4885CSF1R 1465/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | JAK2 2/4885FLT3 118/4885CSF1R 1602/4885 |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | JAK2 468/4885FLT3 645/4885CSF1R 4155/4885 |
| US-20120196876-A1 | (9E)-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZA-TETRACYCLO[18.3.1.1(2.5).1(14,18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | IL17A, SLC25A1, SLC10A1 | JAK2 339/4885FLT3 2000/4885CSF1R 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.